Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $24.65 | Total: $123.25 |
| 1 | 10 | $20.88 | Total: $208.80 |
| 1 | 25 | $17.69 | Total: $442.25 |
| 1 | 50 | $15.08 | Total: $754.00 |
| 1 | 100 | $13.05 | Total: $1,305.00 |
Overview
KBU2046 is an orally administered compound that inhibits cell motility and invasion, effectively suppressing cancer metastasis and extending lifespan. This compound uniquely targets and binds to chaperone heterocomplexes, selectively modifying the interaction of client proteins involved in motility regulation, while avoiding the characteristics typical of classical HSP90 inhibitors.
Chemical Properties
| Molecular Formula | C15H11FO2 |
| Molecular Weight | 242.24 |
| CAS Numbers | 1143863-69-7 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | Fc1ccc(cc1)C1COc2ccccc2C1=O |
Storage and Handling
0C Short Term, -20C Long Term
References
Xu L, et al. Precision therapeutic targeting of human cancer cell motility. Nat Commun. 2018 Jun 22;9[1] 2454.